Long-term follow-up of Dutch Childhood Leukemia Study Group (DCLSG) protocols for children with acute lymphoblastic leukemia, 1984-1991

被引:51
作者
Kamps, WA
Veerman, AJP
van Wering, ER
van Weerden, JF
Slater, R
van der Does-van den Berg, A
机构
[1] Dutch Childhood Leukemia Study Grp, NL-2504 AM The Hague, Netherlands
[2] Univ Groningen, Univ Med Ctr Groningen, Univ Hosp, Beatrix Childrens Hosp, Groningen, Netherlands
[3] Free Univ Amsterdam Hosp, Dept Pediat, Amsterdam, Netherlands
[4] Erasmus Univ, Dept Clin Genet, Rotterdam, Netherlands
[5] Erasmus Univ, Dept Cell Biol & Genet, Rotterdam, Netherlands
关键词
childhood acute lymphoblastic leukemia; long term outcome; CNS prophylaxis; NCI risk classification;
D O I
10.1038/sj.leu.2401964
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Here we report the long-term results of the DCLSG protocols ALL-6 and -7 with special emphasis on the incidence of CNS relapse after treatment without cranial irradiation. In DCLSG protocol ALL-6 (1984-1988), designed for patients with ALL non-high risk (ALL-NHR) (WBC <50 x 10(9)/l, no mediastinal mass, no B cell phenotype and no CNS involvement at diagnosis, comprising 71% of all ALL patients), CNS prophylaxis consisted of a combination of three methods of chemotherapeutic CNS prophylaxis (the use of dexamethasone during induction and maintenance therapy, i.v. medium dose methotrexate and prolonged administration of intrathecal triple therapy). Total duration of treatment: 116 weeks. 190 patients were enrolled in the study. At 10 years, the EFS rate for all patients is 81.5 +/- 2.8%, the survival rate 84.8 +/- 2.7%, and the cumulative incidence of isolated CNS relapse 1.1 +/- 0.8%. The 10-year survival rate for the 139/190 (73.1%) patients with standard risk non-T lineage ALL according to the NCI risk criteria is 80.5 +/- 3.4%. DCLSG protocol-7 was identical to the intensive ALL-BFM-86 protocol, but cranial irradiation was restricted to patients with initial CNS involvement, Patients were stratified into three risk groups (SRG, RG and EG). Treatment duration was 18 months. 218 patients were enrolled in the study. At 10 years, the EFS rate for all patients is 63.4 +/- 3.3%, the survival rate 76.4 +/- 3.0%, the 5-year cumulative incidence of isolated CNS relapse 5.7 +/- 1.8%. The EFS rate at In years of the 127/218 (58.3%) patients with standard risk non-T-lineage ALL according to the NCI risk criteria was 67.9 +/- 4.3%, which is not significantly different from the results achieved in this category of patients with the moderately intensive treatment according to protocol ALL-6 (logrank P= 0.17). These DCLSG studies indicate that omission of cranial irradiation does not jeopardize the overall good results.
引用
收藏
页码:2240 / 2246
页数:7
相关论文
共 16 条
[1]   PROPOSALS FOR CLASSIFICATION OF ACUTE LEUKEMIAS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1976, 33 (04) :451-&
[2]   THE MORPHOLOGICAL CLASSIFICATION OF ACUTE LYMPHOBLASTIC-LEUKEMIA - CONCORDANCE AMONG OBSERVERS AND CLINICAL CORRELATIONS [J].
BENNETT, JM ;
CATOVSKY, D ;
DANIEL, MT ;
FLANDRIN, G ;
GALTON, DAG ;
GRALNICK, HR ;
SULTAN, C .
BRITISH JOURNAL OF HAEMATOLOGY, 1981, 47 (04) :553-+
[3]   Role of cranial radiotherapy for childhood T-Cell acute lymphoblastic leukemia with high WBC count and good response to prednisone [J].
Conter, V ;
Schrappe, M ;
Arico, M ;
Reiter, A ;
Rizzari, C ;
Dordelmann, M ;
Valsecchi, MG ;
Zimmermann, M ;
Ludwig, WD ;
Basso, G ;
Masera, G .
JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (08) :2786-2791
[4]  
Kalbfleisch JD, 1980, STAT ANAL FAILURE TI, P163
[5]  
Kamps WA, 1999, BLOOD, V94, P1226
[6]   ESTIMATION OF TUMOR-CELL MASS IN CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA - PROGNOSTIC-SIGNIFICANCE AND PRACTICAL APPLICATION [J].
LANGERMANN, HJ ;
HENZE, G ;
WULF, M ;
RIEHM, H .
KLINISCHE PADIATRIE, 1982, 194 (04) :209-213
[7]  
Masera G, 1998, INT J PEDIAT HEM ONC, V5, P141
[8]   CHEMOTHERAPY IN 998 UNSELECTED CHILDHOOD ACUTE LYMPHOBLASTIC-LEUKEMIA PATIENTS - RESULTS AND CONCLUSIONS OF THE MULTICENTER TRIAL ALL-BFM-86 [J].
REITER, A ;
SCHRAPPE, M ;
LUDWIG, WD ;
HIDDEMANN, W ;
SAUTER, S ;
HENZE, G ;
ZIMMERMANN, M ;
LAMPERT, F ;
HAVERS, W ;
NIETHAMMER, D ;
ODENWALD, E ;
RITTER, J ;
MANN, G ;
WELTE, K ;
GADNER, H ;
RIEHM, H .
BLOOD, 1994, 84 (09) :3122-3133
[9]  
Riehm H, 1987, Haematol Blood Transfus, V30, P139
[10]  
Slater R M, 1990, Haematol Blood Transfus, V33, P169